BURLINGTON, Mass. / Jun 30, 2025 / Business Wire / Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced public offering of an aggregate of 1,250,000 shares of its common stock (or common stock equivalents in lieu thereof), Series D warrants to purchase up to 1,250,000 shares... Read More

BURLINGTON, Mass. / Jun 27, 2025 / Business Wire / Bone Biologics Corporation (“Bone Biologics” or the “Company) (NASDAQ: BBLG, BBLGW) , a developer of orthobiologic products for spine fusion markets, announces the filing of a patent application with the United States Patent and Trademark Office (USPTO) for its novel NELL-1 protein. The patent application is directed to compositions of rhNELL-1 polypeptide and uses thereof... Read More

BURLINGTON, Mass. / Jun 26, 2025 / Business Wire / Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW) , a developer of orthobiologic products for spine fusion markets, today announced that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the... Read More

BURLINGTON, Mass. / Jun 06, 2025 / Business Wire / Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-6. The reverse stock split will take effect as of 12:01 a.m. ET, on Tuesday, June 10, 2025, and shares of Bone Biologics are... Read More

Brings 30+ years of commercial experience in the orthopedic and spine industry BURLINGTON, Mass. / Oct 21, 2024 / Business Wire / Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW) , a developer of orthobiologic products for spine fusion markets, announces the appointment of Phillip T. Meikle to the Company’s board of directors, effective immediately. Mr. Meikle succeeds Don R. Hankey, who... Read More

BURLINGTON, Mass. / Sep 04, 2024 / Business Wire / Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW) , a developer of orthobiologic products for spine fusion markets , announces that Jeffrey Frelick, chief executive officer, will present virtually at the H.C. Wainwright 26 th Annual Global Investment Conference being held September 9-11, 2024 in New York City. Bone Biologics’ company... Read More

BURLINGTON, Mass. / Aug 02, 2024 / Business Wire / Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW) , a developer of orthobiologic products for spine fusion markets, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 781,251 shares of its common stock having an exercise price of $2.43 per share,... Read More

Reminder: Management “CEO Chat” with Zacks Small-Cap Research Analyst Begins Today at 11 a.m. Eastern Time BURLINGTON, Mass. / Jun 20, 2024 / Business Wire / Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW) , a developer of orthobiologic products for spine fusion markets, announces that the first two patients have been treated in the multicenter, prospective, randomized pilot clinical... Read More

BURLINGTON, Mass. / Mar 06, 2024 / Business Wire / Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW) , a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced public offering of an aggregate of 781,251 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 781,251 shares of... Read More

BURLINGTON, Mass. / Mar 04, 2024 / Business Wire / Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced the pricing of its public offering of an aggregate of 781,251 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 781,251 shares of common stock, at a public... Read More

BURLINGTON, Mass. / Mar 01, 2024 / Business Wire / Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, reports progress with advancing its product candidate NB1 into human clinical testing for spinal fusion. Following Human Research Ethics Committee (HREC) approval last year in Australia for the multicenter, prospective, randomized pilot clinical trial, the Company... Read More

Brings 20+ years of experience in finance and business operations at both public and private life sciences companies BURLINGTON, Mass. / Jan 11, 2024 / Business Wire / Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW) , a developer of orthobiologic products for spine fusion markets, today announced that effective immediately Robert E. Gagnon has been named to the Company’s board of... Read More

BURLINGTON, Mass. / Jan 10, 2024 / Business Wire / Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW) , a developer of orthobiologic products for spine fusion markets, today announced that it has received notice from The NASDAQ Stock Market LLC (Nasdaq) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for... Read More

BURLINGTON, Mass. / Dec 18, 2023 / Business Wire / Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-8. The reverse stock split will take effect as of 12:01 a.m. ET, on Wednesday, December 20, 2023, and shares of Bone Biologics are... Read More

BURLINGTON, Mass. / Nov 20, 2023 / Business Wire / Bone Biologics Corporation (NASDAQ: BBLG) , a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 1,139,063 of its shares of common stock at a purchase price of $0.64 per share. In a concurrent private placement, the Company... Read More

BURLINGTON, Mass. / Nov 16, 2023 / Business Wire / Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,139,063 of its shares of common stock at a purchase price of $0.64 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a... Read More

BURLINGTON, Mass. / Sep 26, 2023 / Business Wire / Bone Biologics Corporation (NASDAQ: BBLG) , a developer of orthobiologic products for spine fusion markets, provides an update on its clinical development initiatives with its NB1 bone graft device. NB1 consists of the recombinant human protein NELL-1 combined with demineralized bone matrix (DBM). The 30-patient pilot study is expected to be conducted in Australia. Earlier... Read More

BURLINGTON, Mass. / Jun 14, 2023 / Business Wire / Bone Biologics Corporation (NASDAQ: BBLG) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for spine fusion markets, today announced the pricing of an underwritten public offering of common stock. Bone Biologics is selling 2,538,071 shares of its common stock in the offering. The shares of common stock are being sold at a price to the public of... Read More

BURLINGTON, Mass. / Jun 06, 2023 / Business Wire / Bone Biologics Corporation (NASDAQ: BBLG) , a developer of orthobiologic products for spine fusion markets, announces that a 1-for-30 reverse stock split became effective on June 5, 2023 and that its common stock and warrants will begin trading on a split-adjusted basis with the open of the market on June 7, 2023. Bone Biologics’ common stock and warrants will continue to... Read More

Company plans to begin 30-patient trial later this year BURLINGTON, Mass. / Apr 11, 2023 / Business Wire / Bone Biologics Corporation (NASDAQ: BBLG) , a developer of orthobiologic products for spine fusion markets, announces that the Human Research Ethics Committee (HREC) has approved Monash Health as the first of a planned multicenter pilot clinical trial to evaluate the Company’s NB1 bone graft in Australia. This pilot... Read More

BURLINGTON, Mass. / Jan 26, 2023 / Business Wire / Bone Biologics Corporation (NASDAQ: BBLG) , a developer of orthobiologic products for spine fusion markets, announces it has engaged Avania as the contract research organization (CRO) for the Company’s pilot clinical trial with NB1. Avania is an integrated global, full-service CRO with specialized expertise in medical devices, novel technology and drug-device combination... Read More